Of 291 clinical samples, 266 showed identical results between EIA and real-time PCR assays, and the concordance rate was 91.4%. To resolve discrepancies, we performed our in-house PCR assay on colonies from a total of 30 culturepositive samples. In-house PCR for toxin A and toxin B detected another 5 positive samples, while repeated real-time PCR assays of these specimens remained negative. However, when real-time PCR was performed using cultured colonies, all 5 specimens were positive. These changes may have been due to differences in the amount of bacteria between the original stool specimens and cultured colonies or the presence of PCR inhibitors in stools.
Feces contain various PCR inhibitors, such as bilirubin, excessive metal cations, and phytic acid. 5 These PCR inhibitors may result in false-negatives; however, since the internal control was positive, this seems unlikely. Two previous studies have evaluated repeated PCR testing for toxin genes, and they reported a few cases that became positive when serial specimens were tested. 6, 7 These results suggest that the amount of bacteria in a specimen may influence the results of PCR assays.
A partially deleted toxin A gene was found in 3 specimens and resulted in approximately 700-base-pair bands after amplification by in-house PCR. These partially deleted toxin A genes were not detected by real-time PCR for the toxin A gene; therefore, positive EIA on these specimens may be due to the detection of toxin B. The binary toxin gene was identified in only 2 strains, while no ribotype 027 was detected. Finally, 10 specimens resulted in false-negative EIA results, while another 5 specimens resulted in falsenegative real-time PCR results.
To ensure detection of toxigenic C difficile strains, some other confirmatory method should be applied to indeterminate clinical specimens. Moreover, repeating PCR tests on cultured colonies might increase the sensitivity of PCR-based methods. laboratory professionals because toxigenic culture is laborintensive and costly, particularly when added to the cost of molecular testing.
Finally, we read with interest the authors' study comparing PCR with EIA, since we are not aware of any study to date that demonstrates equivalence between the 2 diagnostic approaches. We applaud the authors for additionally performing toxigenic culture on all stool specimens in their study and would be interested in full (n = 291) reporting of the diagnostic performance (sensitivity, specificity, positive predictive value, and negative predictive value) of EIA and real-time PCR relative to that gold standard.
